Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Given

Showing results (241-250 of 244) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 244 results.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2023
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancerS Chowdhury, A Bjartell, N Agarwal, et al.
Prostate Cancer and Prostatic Diseases|November 2, 2025
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysisEvan Y Yu, Hiroyoshi Suzuki, Christopher M Pieczonka, et al.
European Urology|July 7, 2023
Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice StatementSriram Deivasigamani, Srinath Kotamarti, Ardeshir R Rastinehad, et al.
Pageof 25

Showing results (241-250 of 244) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 244 results.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2023
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancerS Chowdhury, A Bjartell, N Agarwal, et al.
Prostate Cancer and Prostatic Diseases|November 2, 2025
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysisEvan Y Yu, Hiroyoshi Suzuki, Christopher M Pieczonka, et al.
European Urology|July 7, 2023
Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice StatementSriram Deivasigamani, Srinath Kotamarti, Ardeshir R Rastinehad, et al.
Pageof 25